NCT01856439View on ClinicalTrials.gov

Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

November 30, 2021

Study Completion Date

April 30, 2022

Conditions
Parkinson's Disease
Interventions
DRUG

ProSavin

Long term follow up of patients who received ProSavin in a previous study

Trial Locations (2)

Unknown

Henri Mondor Hospital, Paris

Addenbrookes Hospital, Cambridge

Sponsors

Collaborators (1)

Oxford BioMedica
All Listed Sponsors
collaborator

Oxford BioMedica

INDUSTRY

lead

Axovant Sciences Ltd.

INDUSTRY